Moderna announces update to 2022 supply agreement with gavi that secures access to updated variant-specific covid-19 vaccines for low-and-middle income countries

Given the sufficient supply of covid-19 vaccines globally, moderna & gavi have mutually agreed to cancel remaining pending orders under the current covid-19 vaccine supply agreement for 2022 gavi and moderna have agreed to create a new framework that would enable gavi to purchase up to 100 million doses of updated variant-specific covid-19 vaccines in 2023, with all doses offered at moderna's lowest-tiered price cambridge, ma / accesswire / october 17, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, and gavi, the vaccine alliance, have mutually agreed to cancel remaining pending orders under the current covid-19 vaccine supply agreement for 2022. moderna's agreement with gavi has led to the supply of nearly 70 million doses of covid-19 vaccines to the 92 gavi covax advance market commitment (amc) low- and middle-income countries, in addition to the company facilitating the donation of more than 100 million doses to these countries.
MRNA Ratings Summary
MRNA Quant Ranking